id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-E-6700-0006,FDA,FDA-2017-E-6700,Determinations of Regulatory Review Periods for Purposes of Patent Extensions: RYDAPT,Notice,Determinations,2018-12-28T05:00:00Z,2018,12,2018-12-28T05:00:00Z,2019-06-27T03:59:59Z,2024-03-07T21:04:21Z,2018-28216,0,0,09000064839cbfba
FDA-2017-E-6700-0005,FDA,FDA-2017-E-6700,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2018-12-21T05:00:00Z,2018,12,2018-12-21T05:00:00Z,,2018-12-21T17:40:06Z,,0,0,09000064839c0478
FDA-2017-E-6700-0004,FDA,FDA-2017-E-6700,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2018-10-02T04:00:00Z,2018,10,2018-10-02T04:00:00Z,,2018-10-02T12:54:30Z,,0,0,090000648378ad57
FDA-2017-E-6700-0003,FDA,FDA-2017-E-6700,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2018-01-10T05:00:00Z,2018,1,2018-01-10T05:00:00Z,,2018-01-10T13:12:27Z,,0,0,0900006482dd35f2